Literature DB >> 32240718

COVID-19 in Hemodialysis Patients: A Report of 5 Cases.

Rui Wang1, Cong Liao2, Hong He1, Chun Hu1, Zimeng Wei3, Zixi Hong3, Chengjie Zhang3, Meiyan Liao4, Hua Shui5.   

Abstract

In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in China and spread rapidly worldwide. It is unknown whether hemodialysis patients represent a distinct group of patients with certain characteristics that may make them susceptible to infection or severe disease. In this case report, we describe the clinical and epidemiologic features of COVID-19 infection in 201 maintenance hemodialysis patients in Zhongnan Hospital of Wuhan University, including 5 maintenance hemodialysis patients who contracted COVID-19 infection. Of the 5 patients with COVID-19 infection, one had a definite history of contact with an infected person. The age range of the patients was 47 to 67 years. Diarrhea (80%), fever (60%), and fatigue (60%) were the most common symptoms. Lymphopenia occurred in all patients. Computed tomography of the chest showed ground glass opacity in the lungs of all patients. Up to February 13, 2020, none of the patients had developed severe complications (acute respiratory distress syndrome, shock, or multiple organ dysfunction) or died.
Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; Hemodialysis; SARS-CoV-2; case report; chest radiograph; coronavirus; diarrhea; end-stage renal disease (ESRD); symptoms

Mesh:

Year:  2020        PMID: 32240718      PMCID: PMC7118604          DOI: 10.1053/j.ajkd.2020.03.009

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


Introduction

In December 2019, an outbreak of coronavirus disease (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, and spread rapidly to other areas of China and other countries.1, 2, 3, 4, 5, 6 Phylogenetic analysis suggests that SARS-CoV-2 is a new human-infecting betacoronavirus, closely similar to bat coronaviruses, suggesting that bats may have been the original host of this virus. There are no antiviral drugs of proven efficacy or applicable vaccines. Supportive therapy is the main method for the management of symptomatic patients, many of whom require mechanical ventilation and other intensive care services. There is limited information regarding the epidemiology of COVID-19 in maintenance hemodialysis (MHD) patients. MHD patients may be at increased risk for COVID-19 infection because of many comorbid conditions. In this report, we describe our experience with 5 MHD patients who developed COVID-19 disease at Zhongnan Hospital of Wuhan University.

Case Reports

Among 201 MHD patients in the dialysis center at Zhongnan Hospital of Wuhan University, 5 patients had COVID-19 pneumonia diagnosed according to criteria of the Chinese Centers for Disease Control, which included positive real-time reverse transcriptase–polymerase chain reaction (rRT-PCR) test results for SARS-CoV-2. Characteristics of the 5 patients are presented in Table 1 . The age range of patients was 47 to 67 years and 2 of 5 patients were women. None of the patients had known exposure to the Huanan seafood market that appeared to be the epicenter of this infection. One had known exposure to an infected family member. The most common symptom of the 5 infected patients was diarrhea (4/5), followed by fever (3/5), fatigue (3/5), dyspnea (2/5), and abdominal pain (2/5). Only 1 patient had dry cough. No patient had rhinorrhea, sore throat, myalgia, or other upper respiratory tract infection symptoms. All 5 patients had lymphopenia (lymphocytes <1.0 ×10⁹/L). Only 1 patient had white blood cell and neutrophil cell counts slightly above normal.
Table 1

Patient Clinical and Laboratory Characteristics

Case 1Case 2Case 3Case 4Case 5
Clinical Characteristics
Age, y6162476751
SexMaleMaleFemaleFemaleMale
Contact history with infected personNoNoNoYesNo
Other family members affectedNoNoNoYesNo
Dialysis vintage, y73511
Cause of kidney failureHypertensive nephropathyHypertensive nephropathyChronic nephritisHypertensive nephropathyHypertensive nephropathy
DiabetesNoNoNoYesNo
Signs and symptoms
 FeverYesNoYesYesNo
 Dry coughNoYesNoNoNo
 DyspneaNoNoYesYesNo
 FatigueYesNoNoYesYes
 DiarrheaYesNoYesYesYes
 Abdominal painNoNoYesYesNo
Laboratory Characteristics
White blood cell count, ×103/μL6.847.507.7310.765.03
Neutrophil count, ×103/μL5.695.656.289.244.29
Lymphocyte count, ×103/μL0.630.840.800.920.49
Patient Clinical and Laboratory Characteristics As shown in Figure 1 , ground glass opacities on computed tomography (CT) of the chest were the most common radiologic findings, followed by consolidation. All 5 patients were transferred to a designated hospital after diagnosis to continue hemodialysis. Two of them received intermittent oxygen inhalation through a nasal catheter and treatment with daily 40 mg of methylprednisolone and intravenous immunoglobulin. Two patients were given antiviral treatment with abidol and ribavirin injection, respectively. Up to the end of this study, none of them had developed acute respiratory distress syndrome, shock, or other serious complications.
Figure 1

Computed tomographic scans (transverse plane) of the chest of patients 1 and 3. (A) Patient 1: bilateral ground glass opacity, mainly in the lower lobes of both lungs, with air bronchogram sign. (B) Patient 3: bilateral ground glass opacity of lower lung lobes and round shape consolidation opacity with air bronchogram sign in the right lower lung lobe.

Computed tomographic scans (transverse plane) of the chest of patients 1 and 3. (A) Patient 1: bilateral ground glass opacity, mainly in the lower lobes of both lungs, with air bronchogram sign. (B) Patient 3: bilateral ground glass opacity of lower lung lobes and round shape consolidation opacity with air bronchogram sign in the right lower lung lobe.

Discussion

We describe 5 adult MHD patients in our dialysis center diagnosed with mild COVID-19, representing 2.5% of our dialysis population at the time. In addition, 1 patient had respiratory symptoms and abnormal CT results but negative rRT-PCR results. All patients presented with lymphopenia, and the most common chest radiograph abnormality was ground glass opacity, which bears some resemblance to previous reports. Of note, the prevalence of 2.5% may underestimate the actual prevalence of infected patients. Screening of all MHD patients began after the first patient was identified on February 9, and screening consisted of CT of the chest. rRT-PCR testing was performed only in those with abnormal CT results. In addition, all patients had the temperature measured before dialysis and patients who had a temperature > 37.3°C or with respiratory symptoms underwent CT of the chest and, if abnormal results, rRT-PCR testing. Therefore, some patients may have developed COVID-19 infection before screening and patients without an abnormal CT result at the time of screening would have been missed, although no symptomatic patients were identified before February 9. It has been confirmed that T-cell immunity is a key factor in recovery from SARS-CoV infection. Because uremia status is associated with extensive impairment of lymphocyte and granulocyte function, an abnormal immune system may alter the response to SARS-CoV infection.11, 12 This is of particular concern given the densely populated and busy nature of dialysis facilities, creating a high risk for exposure. However, in our dialysis center, it does not seem to have spread widely. Because the COVID-19 outbreak began in Wuhan, the city in which our dialysis center is located, by January 9, 2020 we had already begun taking a number of measures to avoid infection of patients and staff by SARS-CoV-2. Patients were required to wear surgical masks or N95 masks throughout the hemodialysis treatment. No visitors were allowed. Staff members who conducted the dialysis treatments wore face shields, N95 face masks, eye shields, and disposable gowns, caps, and gloves. In addition, chlorine disinfectants were used daily by staff to disinfect items and floors in the dialysis center. The circulating air UV air sterilizer disinfects 4 times a day for 2 hours each time. In a retrospective study of 1,099 patients with COVID-19 acute respiratory disease, fever and cough were the dominant symptoms, whereas vomiting and diarrhea were rare. Wang et al found that the common symptoms of COVID-19 infection were fever, fatigue, and dry cough, although many patients also presented with gastrointestinal symptoms, such as nausea and diarrhea. Of note, the typical triad of fever, cough, and dyspnea was not present in any of the patients we report here, and diarrhea was a common presenting symptom. Some symptoms of dialysis patients with COVID-19 disease may be difficult to distinguish from other symptoms common among patients receiving dialysis. In summary, we describe 5 MHD patients who developed mild COVID-19 disease. In addition to fever and fatigue, diarrhea was common in our dialysis patients. Further observations will be needed to more fully understand the full spectrum of clinical features and optimal diagnostic and treatment approached for of COVID-19 disease in hemodialysis patients.
  11 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

Review 2.  Immunologic defects and vaccination in patients with chronic renal failure.

Authors:  E L Pesanti
Journal:  Infect Dis Clin North Am       Date:  2001-09       Impact factor: 5.982

3.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

4.  A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan.

Authors:  Ying-Chu Liu; Ching-Hui Liao; Chin-Fu Chang; Chu-Chung Chou; Yan-Ren Lin
Journal:  N Engl J Med       Date:  2020-02-12       Impact factor: 91.245

5.  The first 2019 novel coronavirus case in Nepal.

Authors:  Anup Bastola; Ranjit Sah; Alfonso J Rodriguez-Morales; Bibek Kumar Lal; Runa Jha; Hemant Chanda Ojha; Bikesh Shrestha; Daniel K W Chu; Leo L M Poon; Anthony Costello; Kouichi Morita; Basu Dev Pandey
Journal:  Lancet Infect Dis       Date:  2020-02-10       Impact factor: 25.071

6.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

Review 7.  T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV.

Authors:  William J Liu; Min Zhao; Kefang Liu; Kun Xu; Gary Wong; Wenjie Tan; George F Gao
Journal:  Antiviral Res       Date:  2016-11-11       Impact factor: 5.970

8.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.

Authors:  David S Hui; Esam I Azhar; Tariq A Madani; Francine Ntoumi; Richard Kock; Osman Dar; Giuseppe Ippolito; Timothy D Mchugh; Ziad A Memish; Christian Drosten; Alimuddin Zumla; Eskild Petersen
Journal:  Int J Infect Dis       Date:  2020-01-14       Impact factor: 3.623

9.  Clinical presentation and outcome of severe acute respiratory syndrome in dialysis patients.

Authors:  Ping-Nam Wong; Siu-Ka Mak; Kin-Yee Lo; Gensy M W Tong; Yuk Wong; Chi-Leung Watt; Andrew K M Wong
Journal:  Am J Kidney Dis       Date:  2003-11       Impact factor: 8.860

10.  COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?

Authors:  T Alp Ikizler
Journal:  Am J Kidney Dis       Date:  2020-03-23       Impact factor: 8.860

View more
  54 in total

1.  The Characteristics, Dynamics, and the Risk of Death in COVID-19 Positive Dialysis Patients in London, UK.

Authors:  Dalvir Kular; Irina Chis Ster; Alexander Sarnowski; Eirini Lioudaki; Dandisonba C B Braide-Azikiwe; Martin L Ford; David Makanjuola; Alexandra Rankin; Hugh Cairns; Joyce Popoola; Nicholas Cole; Mysore Phanish; Richard Hull; Pauline A Swift; Debasish Banerjee
Journal:  Kidney360       Date:  2020-09-10

2.  COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab.

Authors:  Cinthia Baldallo; Juan Carlos León Román; Daniel Seron; Irene Agraz; Roser Solans; Natalia Ramos; María José Soler
Journal:  Nefrologia (Engl Ed)       Date:  2021-07-21

3.  Clinical outcomes of hemodialysis patients infected with severe acute respiratory syndrome coronavirus 2 and impact of proactive chest computed tomography scans.

Authors:  Rui Wang; Hong He; Cong Liao; Hongtao Hu; Chun Hu; Juan Zhang; Ping Gao; Xiaoyan Wu; Zhenshun Cheng; Meiyan Liao; Hua Shui
Journal:  Clin Kidney J       Date:  2020-06-12

4.  Comparative incidence and outcomes of COVID-19 in kidney or kidney-pancreas transplant recipients versus kidney or kidney-pancreas waitlisted patients: A single-center study.

Authors:  Carlos A Q Santos; Yoona Rhee; Edward F Hollinger; Oyedolamu K Olaitan; Erik Schadde; Vasil Peev; Samuel N Saltzberg; Martin Hertl
Journal:  Clin Transplant       Date:  2021-05-28       Impact factor: 3.456

5.  Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study.

Authors:  Johan De Meester; Dirk De Bacquer; Maarten Naesens; Bjorn Meijers; Marie M Couttenye; An S De Vriese
Journal:  J Am Soc Nephrol       Date:  2020-11-05       Impact factor: 10.121

Review 6.  Prevalence of Comorbidities in COVID-19 Patients: A Systematic Review and Meta-Analysis.

Authors:  Ashkan Baradaran; Mohammad H Ebrahimzadeh; Aslan Baradaran; Amir R Kachooei
Journal:  Arch Bone Jt Surg       Date:  2020-04

7.  Risk factors for infection and mortality among hemodialysis patients during COVID-19 pandemic.

Authors:  Özgür Can; Gunal Bilek; Sibel Sahan
Journal:  Int Urol Nephrol       Date:  2021-07-05       Impact factor: 2.266

8.  Mortality and associated risk factors of COVID-19 infection in dialysis patients in Qatar: A nationwide cohort study.

Authors:  Tarek Abdel Latif Ghonimi; Mohamad Mahmood Alkad; Essa Abdulla Abuhelaiqa; Muftah M Othman; Musab Ahmed Elgaali; Rania Abdelaziz M Ibrahim; Shajahan M Joseph; Hassan Ali Al-Malki; Abdullah Ibrahim Hamad
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

9.  Mandatory Mask-Wearing and Hand Hygiene Associated With Decreased Infectious Diseases Among Patients Undergoing Regular Hemodialysis: A Historical-Control Study.

Authors:  Jun-Jian Qin; Yan-Fang Xing; Jian-Hua Ren; Yong-Jian Chen; Ying-Fei Gan; Yan-Qiu Jiang; Jie Chen; Xing Li
Journal:  Front Public Health       Date:  2021-06-29

10.  [COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab].

Authors:  Cinthia Baldallo; Juan Carlos León Román; Daniel Serón; Irene Agraz; Roser Solans; Natalia Ramos; María José Soler
Journal:  Nefrologia (Engl Ed)       Date:  2020-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.